Juliana Gurgel-Giannetti, PhD


Ideal Patient Profiles for Spinal Muscular Atrophy Therapies / Perfis ideais de pacientes para tratamento da atrofia muscular espinhal

The expert panel comments on ideal patient profiles for SMA treatment with nusinersen, onasemnogene abeparvovec, and risdiplam. O painel de especialistas comenta os perfis ideais de pacientes para tratamento da atrofia muscular espinhal com nusinersena, onasemnogeno abeparvoveque e risdiplam.

Gerald Grant, MD, FACS


Stanford Children’s Health: A Comprehensive Approach to Care for a Child With a Neurological Condition

Physicians from Stanford Children’s Health offer their keys to successful pediatric neuroscience teams and what to focus on to provide a better quality of life for children.

Darcy Krueger, MD, PhD


Uncovering New, Synergistic Ways to Treat Tuberous Sclerosis Complex: Darcy Krueger, MD, PhD

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on whether the timing and combination of certain therapeutics may impact the long-term care for patients with tuberous sclerosis complex. [WATCH TIME: 3 minutes]

Galit L. Dunietz, PhD, MPH


Understanding the Association Between Obstructive Sleep Apnea Treatment and Dementia Risk: Galit L. Dunietz, PhD, MPH

The assistant professor of neurology at the University of Michigan provided context on a previous study which suggested that treatment of obstructive sleep apnea may reduce the risk of subsequent dementia. [WATCH TIME: 3 minutes]

Brian Wainger, MD, PhD


Expanding the Understanding of ALS With New Methods: Brian Wainger, MD, PhD

The assistant professor of neurology and anesthesiology at Harvard Medical School discussed non-traditional ways ALS research is changing and where the focus should continue to be.

RJ Tesi, MD


Targeting Inflammation to Reduce Effects of Alzheimer Disease: RJ Tesi, MD

The president and chief executive officer of INmune Bio detailed the mechanistic advantages of XPro1595 as a potentially therapeutic benefit for patients with Alzheimer disease and dementia. [WATCH TIME: 5 minutes]

Becky Tilahun, PhD


Improving Recognition, Diagnosis of Psychogenic Nonepileptic Seizures: Becky Tilahun, PhD

The clinical psychologist at Cleveland Clinic provided insight on the tricky nature of diagnosing a patient with nonepileptic seizures and the difficult conversations that can ensue. [WATCH TIME: 3 minutes]

Apirada Thongsing, MD


The Quick Neurologic Examination Tool in the PICU: Apirada Thongsing, MD

The resident physician at Montefiore Medical Center shared her experience with the novel and standardized quick examination tool and the data presented at AAN 2022. [WATCH TIME: 3 minutes]

Brian Hutchinson, PT, MSCS


Quality of Life Improvements in MS Following Wellness Program: Brian Hutchinson, PT, MSCS

The director of the Multiple Sclerosis Achievement Center in Sacramento discussed 3-year data from an assessment of the program, outlining key findings and future research efforts. [WATCH TIME: 6 minutes]

Merit Cudkowicz, MD, MSc


WVE-004 Treatment for C9orf72 ALS and FTD: Merit Cudkowicz, MD

The director of the Sean M. Healey & AMG Center for ALS outlined the trial, which will evaluate ideal dose level and frequency of the investigational treatment for patients with C9-ALS and C9-FTD.

William Ondo, MD


Parkinson’s Disease: Advice for Community Neurologists

Expert neurologists provide insight on how to decide on an on-demand therapy for Parkinson’s disease and provide some general advice.

Stephanie Blandford, MSc


Challenges of Targeting Cytokines in MS: Stephanie Blandford, MSc

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.

Chris Winter, MD


Addressing Unmet Needs in Narcolepsy Management: Practical Insight for Community-Based Physicians

Closing out his discussion on narcolepsy management, Chris Winter, MD, highlights current unmet needs and shares practical advice for community physicians.

James Grotta, MD


James Grotta, MD: The Future of Stroke Care Going into 2021

The vascular neurologist at Memorial Hermann Medical Group explained how clinical stroke care will change in 2021 amid the COVID-19 pandemic.

Gennero Pagano, MD, MSc, PhD


Positive Signs From Prasinezumab in Parkinson Disease: Gennero Pagano, MD, MSc, PhD

The expert medical director at Roche provided detail on results from the phase 2 PASADENA study presented at the 2021 MDS Virtual Congress. [WATCH TIME: 3 minutes]

Mitchell Freedman, MD


The Ever-Expanding Multiple Sclerosis Therapeutics

Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.

Tracey A. Milligan, MD


AUPN Leadership Minute Episode 26: Creating a Formal Junior Faculty Development Plan

Episode 9 of the AUPN Leadership Minute features Tracey A. Milligan, MD, of New York Medical College; and Larry B. Goldstein, MD, of University of Kentucky Medical Center. [WATCH TIME: 8 minutes]

David Bates, PhD


Integrating Machine Learning, Digital Platforms to Alzheimer Trials: David Bates, PhD

The chief executive officer and co-founder of Linus Health discussed screening tools for early cognitive decline and overcoming the complexities with using new-age technology. [WATCH TIME: 3 minutes]

Fred D. Lublin, MD


Future of Relapsing MS Management

Key opinion leaders in multiple sclerosis (MS) discuss the future of relapsing MS management and unmet needs.

Solomon Moshe, MD


Future Aspirations of Neonatal Seizure Research: Solomon Moshe, MD; Elissa Yozawitz, MD

The duo from Montefiore Medical Center discussed aspects of their recently published recommendations on neonatal seizure diagnosis that need further examining.

Bhupendra O. Khatri, MD, FAAN


Navigating an Expanding Treatment Toolbox for MS

“Is more always better?”: The age-old question is more relevant than ever as clinicians and patients alike navigate an increasingly crowded MS treatment landscape.

Marshall C. Freeman, MD, FAHS, FAAN, FAANEM


Optimizing the Migraine Consultation

Proper diagnosis and effective treatment planning can drastically improve quality of life for individuals with migraine.

Marc E. Agronin, MD


Future of Treating Alzheimer Disease

Drs Richard S. Isaacson and Marc E. Agronin look to the future of treating Alzheimer disease with the emphasis on early diagnosis.

Hamid Khoja, PhD


Assessing Efficacy of Fibroblast Cell Technology in MS and Directing Future Clinical Study: Hamid Khoja, PhD

Discussing data from an early safety study, the chief scientific officer of FibroBiologics commented on the benefits of a staggered approach to their clinical research in multiple sclerosis. [WATCH TIME: 5 minutes]

Muhammad "Mud" M Alvi, MD


AUPN Leadership Minute Episode 10: What Your CEO Wants From You

Episode 10 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and Albert L. Wright, Jr., the president and CEO of West Virginia University Health System. [WATCH TIME: 4 minutes]

Dejan Jakimovski, MD, PhD


Next Steps in Understanding Cognitive Decline in Aging MS: Dejan Jakimovski, MD, PhD

The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 4 minutes]

Christina Szperka, MD, MSCE


Conducting Clinical Trials in Pediatric Migraine: Christina Szperka, MD, MSCE

The director of the Pediatric Headache Program at CHOP spoke on the challenges associated with clinical trials in pediatric migraine, further discussing the biggest advance made amid the COVID-19 pandemic. [WATCH TIME: 6 minutes]

Jurriaan Peters, MD, PhD


It Is Time to Redefine Outcomes in Pediatric Epilepsy Surgery

Successful epilepsy surgery in adults has been followed by forced normalization, depression, and memory issues, resulting in questions about the use of the metrics in the study of broader outcomes—a problem even more prominent in pediatric epilepsy surgery.

© 2023 MJH Life Sciences

All rights reserved.